NeuBase Therapeutics Stock Target Price and Analyst Consensus
NBSE Stock | USD 0.44 0.02 4.76% |
The current analyst and expert consensus on NeuBase Therapeutics is Hold, with no strong buy opinions. The current projected NeuBase Therapeutics target price consensus is 140.00 with 1 analyst opinions. The most common way NeuBase Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview NeuBase Therapeutics executives and customers to further validate their buy or sell advice. Please note, the number of analysts providing the opinion is not sufficient to provide adequate consensus on NeuBase Therapeutics. We encourage you to use your own analysis of NeuBase Therapeutics to validate this buy or sell advice. NeuBase Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected NeuBase Therapeutics target price to derive its highest and lowest estimates based on its projected price volatility. Check out Macroaxis Advice on NeuBase Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.
Lowest Forecast 127.4 | Highest Forecast 155.4 | Target Price 140 |
NeuBase |
It's important to approach NeuBase Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize NeuBase Therapeutics price targets
NeuBase Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using NeuBase Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at NeuBase Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if NeuBase Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional NeuBase Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of NeuBase Therapeutics is a key component of NeuBase Therapeutics valuation and have some predictive power on the future returns of a NeuBase Therapeutics.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of NeuBase Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.Impulse Invested over 100 shares | ||
Dividend Beast Invested over 60 shares | ||
Warren Buffett Holdings Invested few shares | ||
Banking Invested over 40 shares | ||
Check out Macroaxis Advice on NeuBase Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for NeuBase Stock analysis
When running NeuBase Therapeutics' price analysis, check to measure NeuBase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuBase Therapeutics is operating at the current time. Most of NeuBase Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuBase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuBase Therapeutics' price. Additionally, you may evaluate how the addition of NeuBase Therapeutics to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Stocks Directory Find actively traded stocks across global markets | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
The data published in NeuBase Therapeutics' official financial statements usually reflect NeuBase Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of NeuBase Therapeutics. For example, before you start analyzing numbers published by NeuBase accountants, it's critical to develop an understanding of what NeuBase Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of NeuBase Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, NeuBase Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in NeuBase Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of NeuBase Therapeutics. Please utilize our Beneish M Score to check the likelihood of NeuBase Therapeutics' management manipulating its earnings.